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Hepatitis C virus (HCV) is a major cause of cirrhosis and hepatocellular carcinoma (HCC)
making the virus the most common cause of liver failure and transplantation. HCV is
estimated to chronically affect 130 million individuals and to lead to more than 350,000
deaths per year worldwide. A vaccine is currently not available. The recently developed
direct acting antivirals (DAAs) have markedly increased the efficacy of the standard of care
but are not efficient enough to completely cure all chronically infected patients and their
toxicity limits their use in patients with advanced liver disease, co-morbidity or transplant
recipients. Because of the host restriction, which is limited to humans and non-human
primates, in vivo study of HCV infection has been hampered since its discovery more than
20 years ago.The chimpanzee remains themost physiologicalmodel to study the innate and
adaptive immune responses, but its use is ethically difficult and is now very restricted and
regulated. The development of a small animal model that allows robust HCV infection has
been achieved using chimeric liver immunodeficient mice, which are therefore not suitable
for studying the adaptive immune responses. Nevertheless, these models allowed to go
deeply in the comprehension of virus-host interactions and to assess different therapeutic
approaches. The immunocompetent mouse models that were recently established by
genetic humanization have shown an interesting improvement concerning the study of
the immune responses but are still limited by the absence of the complete robust life cycle
of the virus. In this review, we will focus on the relevant available animal models of HCV
infection and their usefulness for deciphering the HCV life cycle and virus-induced liver
disease, as well as for the development and evaluation of new therapeutics. We will also
discuss the perspectives on future immunocompetent mouse models and the hurdles to
their development.
Keywords: hepatitis C virus, liver disease, hepatocellular carcinoma, animal models, antivirals, immunocompetent
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INTRODUCTION
Hepatitis C virus (HCV) is a small enveloped positive sense single-
stranded RNA virus from the Flaviviridae family (Lindenbach
et al., 2007). HCV is one of the main causative agents of liver
disease worldwide and a major problem of public health with
approximately 130 million chronically infected people and more
than 350,000 deaths each year. Moreover, the World Health Orga-
nization estimates that three to four million people are newly
infected every year. No vaccine is available so far, and the cur-
rent standard of care combination treatment of interferon-alfa
(IFNα) and ribavirin is not effective against allHCVgenotypes and
often not well tolerated by the patients (Poordad and Dieterich,
2012). The recently developeddirect-acting antivirals (DAAs) have
significantly improved the treatment of chronic HCV infection
(Poordad and Dieterich, 2012) but can lead to the selection of
DAA-resistant viral variants (Pawlotsky, 2011; Aloia et al., 2012).
Abbreviations: HCV, hepatitis C virus; HCC, hepatocellular carcinoma
Thus, despite the advances made in recent years, HCV infection
remains a global health problem. Furthermore, a vaccine is not
available. Research efforts are thus still to be continued in order
to decipher the details of the viral life cycle within its host and to
propose new therapeutic alternatives to improve patient care.
Improvedunderstanding of the phenomena related to the inter-
action of the virus with its host, in its entirety, relies on the use
of a model allowing the study of the whole viral life cycle as well
as the host responses against the virus, especially the immune
responses. Only the use of a living organism allows to achieve
this goal. Chimpanzees are the only animals reliably support-
ing HCV infection and allowing the study of anti-viral immune
responses even though they do not develop fibrosis and cirrhosis
and very rarely hepatocellular carcinoma (HCC; Muchmore et al.,
1988; Lanford et al., 2001). However, the use of chimpanzees in
medical research is ethically very controversial and increasingly
limited (Harrington, 2012). To overcome this hurdle, small ani-
mal models have been developed during the last decade. Mouse
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models are of particular interest since mice are easy to breed and
handle and can be genetically modified.
In this review, we will discuss the advantages and limitations
of the different animal models regarding their potential in leading
to a better comprehension of virus-host interactions and HCV
pathogenesis, as well as their utility for preclinical evaluations
prior translation to clinical trials in human.
NATURALLY HCV PERMISSIVE ANIMAL MODELS
Highly genetically HCV-related viruses from the hepacivirus gen-
der can infect new world primates (Muerhoff et al., 1995; Simons
et al., 1995), dogs (Kapoor et al., 2011), horses (Burbelo et al., 2012;
Lyons et al., 2012) and bats (Quan et al., 2013). But so far, HCV
was only found to infect few species other than human (reviewed
in Simmonds, 2013), chimpanzees and non-rodent smallmammal
northern treeshrew (Tupaia belangeri).
CHIMPANZEES
Chimpanzees are tightly linked to the history of HCV discovery
(Houghton, 2009). These animals can be chronically infected with
the virus, using various sources as inoculum. Although the clinical
course of HCV infection in chimps and humans is not identi-
cal (Bukh, 2004), chimp studies have greatly contributed to our
understanding of innate and adaptive immune responses in the
course of HCV infection (Bowen and Walker, 2005; Rehermann,
2009). A large body of evidence indicates that T cell responses play
a major role in viral clearance as well as protection from HCV
infection (Neumann-Haefelin and Thimme, 2013). Indeed,mem-
ory T cells as well as the activation of intra-hepatic natural killer
(NK) cells and type I/II interferon production were demonstrated
to prevent HCV re-infection in chimpanzees (Nascimbeni et al.,
2003; Barth et al., 2011). Moreover, neutralizing antibodies may
also contribute to protection fromHCV infection in these animals.
Chimpanzees have also been very valuable for the evaluation of
various antivirals and to date, chimpanzees are the only animals
permitting extensive evaluationof the efficacy of potential vaccines
against HCV (Houghton, 2011). It has especially been shown that
therapeutic vaccines including structural proteins are better T cell
stimulators than vaccines where only non-structural proteins are
present (Dahari et al., 2010). But so far, it was not possible to
clearly identify a safe and effective vaccine for humans (Bailey,
2010).
Despite the fact that studies of HCV infection in chimpanzees
have greatly advancedour understanding of the immune responses
that are required to efficiently clear viral infection, several limita-
tions of this model have to be pointed out (Table 1). Indeed,
data from chimpanzee studies are highly variable and difficult to
interpretmainly because of the biological variability between indi-
vidual animals and the small animal cohorts. Moreover, chronic
infection appears in only 30–40% of infected animals while it can
reach 85% in humans (Lanford et al., 2001). Furthermore, chron-
ically infected chimpanzees do not readily develop cirrhosis or
fibrosis and have much milder symptoms (Bukh et al., 2001). It
is worth noting that HCC is only rarely observed in chimpanzees
(Muchmore et al., 1988; Lanford et al., 2001). Finally, the lim-
ited availability, the cost for acquiring and maintaining animals
as well as ethic considerations have also been major drawbacks
to the use of this animal model. Indeed, the use of chimpanzees
for biomedical and behavioural research is now legally forbid-
den in Europe since the new European Directive 2010/63 and has
been recently banned by the NIH (Harrington, 2012) following
the recommendations of the Institute of Medicine (Altevogt et al.,
2011).
Tupaia belangeri
Tupaia belangeri, or Northern treeshrew, is a non-rodent small
mammal susceptible to HCV infection (Xie et al., 1998; Xu et al.,
Table 1 | Current animal models for the study of HCV infection.
Chimpanzee Tree shrew uPA-SCID FRG AFC8-huHSC/Hep Rosa26-FLuc Rat
HCV entry Yes Yes Yes Yes Yes Yes Yes
HCV production Yes Yes Yes Yes No No Yes
Viremia Weaker than in
humans
Low High High No No Low
HCV pathogenesis Milder than in
humans, HCC?
Hepatitis, fibrosis,
cirrhosis
No No Fibrosis N/A Hepatitis
Immune response Yes Yes No No Yes Yes No
MHC match Immune
system/ hepatocytes
Yes Yes N/A N/A Yes Yes No
MHC match Immune
system/host
Yes Yes N/A N/A No Yes Yes
Vaccine development Yes Possible No No Yes No No
HCC, hepatocellular carcinoma; N/A, not applicable.
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2007; Amako et al., 2010). HCV entry factors CD81, scavenger
receptor class B type I (SR-BI), claudin-1 (CLDN1) and occludin
(OCLN) from tupaia origin have been shown to promote entry of
HCV pseudoparticles or cell culture-derived HCV (HCVcc) into
human or mouse cells engineered to express these host factors
and primary tupaia hepatocytes are able to support HCV infec-
tion (Zhao et al., 2002; Barth et al., 2005; Tong et al., 2011). This
model has recently been used to perform a metabolomic analysis
upon HCV infection (Sun et al., 2013). In this study, the authors
performed comprehensive metabolomics profiling and pathway
analysis of large biological data sets in order to identify signaling
pathways associated with HCV infection, but the HCV infection
level of the animals was not clearly stated. Another study assessed
the protective effect of xanthohumol, a main prenylated chalcone
from hops, on HCV-induced hepatitis (Yang et al., 2013). Even
though the authors were able to detect liver injury and HCV Core
protein expression in the liver of HCV inoculated animals, neither
serum HCV RNA nor anti-HCV antibodies could be detected.
Indeed, despite the development of chronic liver disease in some
animals, the infection rate of tupaia is weak and viremia appears
to be low and rarely sustained (Xu et al., 2007; Amako et al., 2010;
Table 1). Moreover, the limited availability of these animals, their
cost of housing and the absence of tupaia-specific reagents to assess
HCV-host interactions in this model still limit the use of tupaia
for the study of HCV pathogenesis and vaccine design. The devel-
opment of tupaia-adapted viruses may be one strategy to make
this model more efficient and robust.
RODENT MODELS OF HCV INFECTION
Mice and rats are naturally resistant to HCV infection as rodent
hepatocytes donot supportHCVentry and replication (Ploss et al.,
2009; Dorner et al., 2011). It is worth noting that in contrast to
the early steps of the viral life cycle, HCV assembly and release
do not appear to be restricted in mouse cells (Long et al., 2011;
Vogt et al., 2013). With the advent of transgenic technology dif-
ferent mouse models for the study of HCV infection could be
engineered. Several transgenic mice carrying different parts of the
HCV genomewere the first availablemousemodels to studyHCV-
host interactions (reviewed in Lerat et al., 2011; Billerbeck et al.,
2013). These mice display liver pathologies mimicking human
disease, principally steatosis and primary liver cancer. However, in
contrast to the human setting, as the mouse immune system toler-
ates the transgenically expressed viral proteins, liver pathogenesis
establishes in the absence of local inflammation. Moreover, the
absence of active HCV RNA replication in these mice precludes
the study of HCV infection. Research efforts thus further focused
on developing rodent models supporting productive HCV infec-
tionmainly by humanizingmice or rats to render them permissive
toHCV.Humanization can be achieved by two different strategies:
(i) xenografting human cells or (ii) transgenesis.
THE uPA-SCID MOUSE MODEL
These immunodeficient (SCID) mice with hepatocyte-lethal phe-
notype due to the overexpression of the urokinase-type plasmino-
gen activator (uPA) transgene in their liver can be efficiently
engrafted with primary human hepatocytes in order to initiate
infection with HCV (Table 1). The uPA-SCID mouse model was
for the first time described more than 10 years ago (Mercer et al.,
2001). It has been shown that the liver of these chimeric mice
can be nearly completely repopulated by the transplanted human
hepatocytes (Tateno et al., 2004). Such human liver chimeric mice
then become susceptible to HCV infection. Following viral inoc-
ulation, HCV titers of more than 107 IU/mL can been observed
(Hiraga et al., 2007; Vanwolleghem et al., 2010) and viral infec-
tion can be sustained up to 10 months (Mercer et al., 2001). As
for chimpanzees, in addition to HCV-positive patient-derived
serum of different genotypes (Mercer et al., 2001; Hsu et al.,
2003; Bukh et al., 2010), HCVcc may also be used to inoculate
these mice (Lindenbach et al., 2006; Akazawa et al., 2013) and
this thus enables researchers to study a wide variety of different
inocula.
The uPA-SCID model has been extensively used to evaluate
different strategies to prevent or treat HCV infection. Targeting
cell entry of the virus is one of these approaches. HCV entry is
a crucial step to establish infection and can be blocked by using
neutralizing antibodies binding to the virions or by monoclonal
antibodies (mAbs) targeting host entry factors. Studies using neu-
tralizing antibodies purified from blood of a genotype 1a infected
patient demonstrated the efficacy of this approach to inhibit
viral infection with homologous and heterologous HCV strains
(Vanwolleghem et al., 2008; Meuleman et al., 2011b). Another
study assessed the potential of neutralizing mAbs from a phage
display library constructed from the bone marrow mononuclear
cell RNA of a chronically infected patient (Law et al., 2008). These
antibodies have been shown to bind to the HCV envelope gly-
coprotein E2 and to exhibit broadly cross-neutralizing activity
against heterologous HCV quasispecies in the uPA-SCID model.
In addition to antibodies targeting the virus, HCV entry can also
been inhibited by targeting host factors essential for this process
(Zeisel et al., 2013). MAbs against the HCV entry factors CD81
(Meuleman et al., 2008) and SR-BI (Lacek et al., 2012; Meuleman
et al., 2012) havebeen successfully tested in the chimeric uPA-SCID
mouse model and were proven to be efficient at inhibiting HCV
infection in challenge studies with different genotypes. Moreover,
chimeric-liver mice that were already infected for 3 days could still
be efficiently treated with five injections of 400 µg of anti-SR-BI
mAb (Lacek et al., 2012; Meuleman et al., 2012). The uPA-SCID
model has also been successfully used to assess the efficacy of
smallmolecule drugs (Lupberger et al., 2011; Sainz et al., 2012) and
various other molecules targeting host entry factors (Matsumura
et al., 2009; Meuleman et al., 2011a). Indeed, administration of
the clinically approved drug erlotinib, which specifically targets
the tyrosine kinase activity of epidermal growth factor receptor
(EGFR), significantly delayed the kinetics of HCV infection with
a genotype 2a infectious serum (Lupberger et al., 2011). Another
study showed that pretreatment with ezetimibe, an antagonist of
theHCVco-entry factorNiemann-PickC1-like1 (NPC1L1), could
prevent infection of some chimeric mice infected with a genotype
1b virus (Sainz et al., 2012).
Moreover, the uPA-SCIDmousemodel has also been efficiently
used to assess the efficacy of recently developed DAAs specifically
targeting HCV encoded proteins required for viral replication.
One of the first HCV protease inhibitor, BILN 2061, has been
evaluated by Vanwolleghem et al. (2007) in this mouse model.
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Although the authors could see a very rapid viral load decline of
about 2.5 log10 after a 4-day treatment, they also observed a dete-
riorating effect of this compound on the mouse cardiomyocytes.
This latter observation confirmed results already seen in rhesus
monkeys where BILN 2061 also induced cardiotoxicity (Reiser
et al., 2005). Of note, the clinical development of BILN 2061
was halted due to these toxic effects. More recently, the clinically
licensed NS3-4A protease inhibitor telaprevir has been evaluated
in this model, alone (Kamiya et al., 2010) or in combination with
the NS5B inhibitor MK-0608 (Ohara et al., 2011). Furthermore,
a study by Shi et al. (2013) evaluated the antiviral activity of dif-
ferent combinations of DAAs against genotype 1b, 2a, and 2b in
these mice. The authors assessed the effect of the NS3 protease
inhibitor BMS-605339, the NS5A inhibitor BMS-788329 and the
NS5B non-nucleoside analog inhibitor BMS-821095 and showed
that different combination therapies were very efficient against
genotype 1b virus but not against genotype 2a or 2b strains. Qua-
sispecies population before and after treatment as well as selection
of mutations leading to the appearance of resistant variants were
also analyzed by ultra deep sequencing in these animals (Shi et al.,
2013). Furthermore, several other compounds with an effect on
viral replication have also been tested with success as monother-
apy against HCV infection (Nakagawa et al., 2007; Kneteman et al.,
2009; Narjes et al., 2011).
The uPA-SCIDmousemodel has further been used to study the
relevance of the genetic polymorphism near the interleukin-28B
(IL-28B) region described to be associated with a better response
to IFNα and ribavirin in patients (Ge et al., 2009; Suppiah et al.,
2009; Tanaka et al., 2009). In this study, Watanabe et al. (2012)
showed that therewas no significant difference in response to IFNα
treatment in mice with human hepatocytes with different types of
polymorphism indicating that the effect observed in patients was
attributable to their immune responses, since these mice do not
have an adaptive immune system.
Although the uPA-SCIDmousemodel has proven its usefulness
and has become relevant for the preclinical evaluation of novel
antiviral compounds, this model has several limitations. Indeed,
these mice are very fragile and have to be engrafted within the first
weeks of life given that these animals are born with a hepatocyte-
lethal phenotype (Meuleman et al., 2005; Vanwolleghem et al.,
2010). Moreover, the uPA transgene can be deleted in some mice
leading to the restoration of a wild-type phenotype and thus loss
of the human hepatocyte graft (Sandgren et al., 1991). Another
drawback of this model is the absence of a functional adaptive
immune system. Due to the severe combined immunodeficiency
background, these mice are deficient in functional mature T and
B cells. Therefore, they cannot be used for the study of adaptive
immune responses or for the evaluation of vaccines. Nevertheless,
this model is not devoid of innate immunity and has been used
to decipher HCV specific innate immune responses (Walters et al.,
2006).
The Fah−/− Rag2−/− γ-c−/− (FRG) MOUSE MODEL
In order to overcome some of the limitations of the uPA-SCID
mouse model, another model has been developed using immun-
odeficient mice with genetic alterations leading to a hepatocyte-
lethal phenotype. These “FRG” mice are deficient for the Rag2
recombinase and the common γ -chain of the interleukin recep-
tors, leading to a more profound immunodeficiency (Goldman
et al., 1998; Mazurier et al., 1999). Moreover, they are deficient
for the tyrosine catabolic enzyme fumarylacetoacetate hydrolase
(Fah), which leads to liver degeneration (Grompe et al., 1993,
1995; Overturf et al., 1996). In this model, liver degeneration can
be prevented as long as the 2-(2-nitro-4-trifluoromethylbenzoyl)-
1,3-cyclohexanedione (NTBC) drug is provided to themice. Thus,
the time of transplantation of human hepatocytes is easier to con-
trol than in the uPA-SCID mouse model since it can be done at
anytime in adult mice upon drug withdrawal. Moreover, in con-
trast to the uPA-SCIDmouse model, spontaneous reversion of the
hepatocyte-lethal phenotype does not occur since there is a full
deletion within the Fah encoding gene (Grompe et al., 1993).
Upon NTBC withdrawal, FRG mice can be efficiently trans-
planted with human hepatocytes to obtain liver repopulation
(Azuma et al., 2007; Bissig et al., 2007). Moreover, Bissig et al.
(2010) successfully infected these transplanted mice with a geno-
type 2a HCV JFH-1 strain, a clinical isolate of HCV genotype
1a and chimeric genotype 1a/2a and 1b/2a viruses. Up to now,
this study is the only one reporting HCV infection in the FRG
model. Although this chimeric liver mouse model has so far been
less extensively used than the uPA-SCID model, it should be as
efficient to allow preclinical evaluation of antiviral compounds
(Table 1) and several reports using this model are expected within
the next years.
Like the uPA-SCID mouse model, the FRG model suffers from
a lack of an immune system. Due to the Rag2 and γ -c deficiencies,
these mice do not harbor T-, B- and NK-cells. These animals
are therefore not more suitable than the uPA-SCID mice for the
study of HCV immunopathogenesis and for the development and
evaluation of vaccines.
AFC8-huHSC/Hep MICE
Recently, another model of HCV permissive mice has been devel-
oped to overcome the lack of immunity intrinsic to the uPA-SCID
and FRGmodels. This model is based on immunodeficient Balb/c
Rag2−/− γ -c−/− (BRG) mice that have been genetically mod-
ified to overexpress in the mouse liver a fusion protein of the
FK506 binding protein (FKPB) and caspase-8 under the albumin
promoter (AFC8; Washburn et al., 2011). Injection of AP20187
induces the homodimerization of the caspase-8 active domain
leading to a suicidal activity of this enzyme and thus death of
mouse hepatocytes (Pajvani et al., 2005). This induced hepatode-
ficiency improves the engraftment of human hepatocytes. These
transgenic mice can therefore be transplanted, within the 5 first
days of life, with human hepatocyte progenitor cells and CD34+
hematopoietic stem cells derived from the same fetal liver allow-
ing human leukocyte antigen (HLA)matching between these cells.
Following injection of AP20187, the authors demonstrated devel-
opment of human immune cells and human hepatocytes in these
mice. About 50% of these AFC8-huHSC/Hep mice were subse-
quently effectively infected with patient serum-derived HCV of
genotype 1a but HCV RNA could only be demonstrated in the
liver of these animals. No HCV RNA was detected in the blood
of infected mice. Despite this absence of viremia, the authors
observed human immune cell infiltration in the liver of HCV+
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mice as well as HCV-specific CD4 and CD8 T cell responses.
Specific B cell responses could not be observed in these ani-
mals. Interestingly, half of these HCV+ mice developed severe
portal fibrosis with numerous septa. This was the first report on
a small animal model of HCV infection exhibiting development
of HCV-specific adaptive immune responses and virally induced
immunopathogenesis (Table 1).
Although these mice represent a first breakthrough for the
development of a fully immunocompetent mouse model for the
study of HCV infection, the absence of serum HCV particles and
the lack of fully functional B cells are important issues for the
evaluation of potential antiviral drugs and vaccines. Furthermore,
the education of the immune system from human HSC is done
on the murine major histocompatibility complex (MHC). It is
not yet clear whether the selection of human immune cells on
mouse MHC will allow proper recognition of HCV infected HLA
expressing humanhepatocytes and be comparablewith the human
setting.
Rosa26-Fluc HCV ENTRY FACTOR HUMANIZED MICE
Another model of immunocompetent mice permissive to HCV
infection has been developed shortly after the AFC8-huHSC/Hep.
In contrast to the previous model, these mice have a fully
functional murine immune system and liver. To overcome the
species-specific restriction of viral entry and to achieve HCV
susceptibility of the mouse liver, the authors targeted the mouse
hepatocytes in vivo with adenoviral vectors to express humanHCV
entry factors CD81, SR-BI, CLDN1, and OCLN (Dorner et al.,
2011; Figure 1). About 5% of the murine hepatocytes expressed
all four human entry factors upon adenoviral transduction. The
Rosa26-Fluc background of these mice allows to detect viral entry
by in vivo bioluminescence. Indeed, as HCV does not efficiently
replicate inmouse cells (Zhu et al., 2003; Uprichard et al., 2006; Lin
et al., 2010), Dorner et al. (2011) engineered the virus to express
the Cre recombinase (HCV-CRE). This latter, once expressed in
the mouse liver, leads to the activation of a loxP-flanked luciferase
reporter in the genome of the Rosa26-Fluc mice (Safran et al.,
2003). The emitted photons then reflect viral entry into hepa-
tocytes. This model was successfully used to study for the first
time entry of HCVcc chimeras of different genotypes into mouse
hepatocytes in vivo.
The authors also assessed the efficacy of anti-CD81 and anti-E2
antibodies on HCV entry as well as a prophylactic vaccine based
on recombinant vaccinia virus encoding HCV proteins from Core
to NS2 of genotype 1a.With this vaccine approach, robust titers of
anti-E2 antibodies and a decreased susceptibility to heterologous
challenge with HCV-CRE harboring structural proteins of geno-
types 1b, 2a, or 4a was observed. This is the first report of the usage
of a fully immunocompetent small animal model for the study of
HCV infection and, so far, this model is the only available mouse
FIGURE 1 | Currently explored approaches aiming at developing new
animal models for the study of hepatitis C virus infection. From left to
right: xenotransplantation of human cells, genetic humanization by expression
of defined human specific factors, viral adaptation of HCV to mouse cells.
HLA transgenic mice can be crossed with the different models in order to
improve immune responses.
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model for combined immunization and challenge studies. This is
also the only mousemodel with a perfect MHCmatching between
the immune system and infected hepatocytes, which would allow
a better understanding of the entire immune responses induced
by the virus (Table 1).
Although conceptually markedly advancing the field, the
humanized Rosa26-Fluc model still has its limitations. First, there
is no virus production by the infected mouse hepatocytes due to
inefficient viral replication in these cells. This makes this model
unsuitable for the evaluation of DAAs or antivirals targeting the
assembly and egress steps of the viral life cycle. Moreover, the
usage of adenoviral vectors to introduce the human entry fac-
tors into mouse hepatocytes leads to the induction of an immune
response against the vector. This renders the study of HCV-specific
immune responses difficult since the induction of interferon stim-
ulated genes (ISGs) and a rapidNKcell-mediated innate immunity
lead to the loss of adenovirus-transduced hepatocytes and there-
fore to the loss of HCV infected cells. Thus, it is not possible
to study HCV-induced immunopathogenesis in this model. This
model is currently being extended by developing transgenic mice
stably expressing the human HCV entry factors and ultimately
further engineering the mouse hepatocytes to support HCV repli-
cation. A first transgenic mouse expressing human CD81, SR-BI,
CLDN1, and OCLN did not appear to be susceptible to HCV
entry (Hikosaka et al., 2011) but technical limitations may have
precluded detection of viral entry in this study. Follow-up stud-
ies using human entry factor transgenic mice are thus awaited
to assess the potential of such mice for further studying HCV
pathogenesis.
IMMUNOCOMPETENT RAT MODEL
Another immunocompetent small animal model susceptible to
HCV infection was generated using rats tolerant to human hep-
atocytes (Ouyang et al., 2001). Fetal rats were intraperitoneally
injected with human hepatomaHuh7 cells between 15 and 17 days
of gestation in order to induce a specific tolerance of the rat
immune system toward these cells. This tolerance allows the trans-
plantation of Huh7 cells via an intrasplenic injection in newborn
rats, within 24 h of birth. This results in survival of these cells
without rejection by the rat immune system as demonstrated by
human albumin detection in the liver as well as in the serum of
the tolerized transplanted rats (Ouyang et al., 2001). These rats
may then be inoculated with serum-derived HCV of genotype 1
one week after transplantation and are able to develop transient
viremia as shown by an HCV viral load of 2 × 104 copies/mL by
week 12 (Wu et al., 2005). Infected animals where characterized
by inflammation of the liver as demonstrated by elevated serum
alanine aminotransferase with a peak at week 13 as well as by
mononuclear cell infiltration in the liver (Table 1).
Unfortunately, the set-up of this model is difficult since the
intraperitoneal injection in fetal rats is challenging. Moreover, this
model is limited by the fact that the transplanted cells are not
primary human hepatocytes but a human hepatoma cell line. Fur-
thermore, the number of transplanted cells is low and viremia
remains weak, around 2 × 104 copies/mL, in comparison to viral
loads observed in HCV-infected patients or human liver chimeric
mice. Despite the fact that this animalmodel is immunocompetent
and can be infectedwithHCV, themismatch between humanHLA
and rat MHC prevents the study of adaptive immune responses
against infected hepatoma cells. It is worth noting that this model
has not been extensively used so far and only one publication
reported its usage (Wu et al., 2005). Further reports would thus be
useful in order to compare the potential of thismodel to the poten-
tial of the different mouse models to study HCV pathogenesis and
assess antiviral strategies.
FUTURE DIRECTIONS
In the past years,muchprogress has beenmade indevelopingnovel
animal models for the study of HCV-host interactions. The major
drawbacks of the different small animalmodels described so far are
(i) absent or not fully functional adaptive immunity, (ii) low-level
viral replication and absent viremia and consequently (iii) absent
or low fibrosis and no cirrhosis. The uPA-SCID and FRG mod-
els both lack T and B cells. The AFC8-huHSC/Hep model is
characterized by a human immune system educated on murine
MHC molecules and absent viremia. The Rosa26-Fluc model has
matchedmurine immune cells and hepatocytes but these latter are
unable to efficiently replicate the viral genome and to egress the
virus. Finally, the immune system of the immunocompetent rat
model does not match the HLA molecules at the surface of the
transplanted human hepatoma cells. Thus, additional immuno-
competent mouse models need to be developed to study different
aspects of HCV pathogenesis in the context of robust viral replica-
tion. So, ultimately, what would be the best model to study HCV
infection? Different lines of development are currently pursued:
(i) adapting the virus to mice to allow the virus to accomplish its
entire life cycle inmouse hepatocytes, (ii) further humanizingmice
to render these animals permissive to HCV and (iii) combining
these two approaches (Figure 1).
HCV-ADAPTED IMMUNOCOMPETENT MOUSE MODEL
Given that mouse hepatocytes are resistant to HCV infection, a
possibility to overcome this species-specific restriction of viral
infection without genetically engineering the host is to adapt the
virus to mouse cells, i.e., develop a virus able to complete its whole
life cycle - entry, translation, replication, egress – in normal mouse
hepatocytes (Figure 1). Bitzegeio et al. (2010) have explored this
trail by the selection of a HCV Jc1-derived mutant (genotype 2a)
adapted to the murine entry factor CD81. In contrast to wild-type
Jc1, this HCVmutant is able to enter cells expressingmouse CD81.
However, despite efficiently entering mouse cells, this selected
HCV strain is unable to replicate in mouse hepatocytes, indicating
that host factors limit productive infection downstream of virus
cell entry (Bitzegeio et al., 2010). Several lines of evidence indicate
that innate immune responses interfere with HCV replication and
although HCV has evolved strategies to evade innate immunity in
human cells, this may be less efficient in mouse cells (Lin et al.,
2010; Billerbeck et al., 2013; Schoggins and Rice, 2013; Vogt et al.,
2013). So potentially the selection of a mouse innate immune
response-insensitive HCV strain might overcome the limitations
imposed by mouse hepatocytes and lead to the development of
viremia in immunocompetent mice. However, even though such
a model might be achievable, it will remain to be determined to
which extent it would be comparable toHCV infection in humans.
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In order tomimicmore precisely the human immune response,
it might be of interest to use HLA expressing mice (Pajot et al.,
2004), in line with a recent study where hepatitis B virus genome
was introduced into the liver of HLA-A2/DR1 mice (Dion et al.,
2013). However, the main limitation of such an approach is the
fact that it will be very difficult to mimic the variability of HLA
combinations present in humans. Thus, efforts should focus on
defined HLA transgene combinations. Nevertheless, there is no
certainty that the mouse immune responses developed against the
virus would be comparable to those observed in human (Mestas
and Hughes, 2004).
Therefore, another strategy to generate a fully immunocom-
petent mouse model for the study of HCV infection is to focus
on the development of mice with humanized immune system and
humanized liver (hu-IS/hu-Hep mice).
HUMAN IMMUNE SYSTEM – HUMAN HEPATOCYTE CHIMERIC MOUSE
MODEL
The optimal way to assess the role of the immune system
in response to HCV infection and to explore virus-induced
immunopathogenesis in a setting comparable to humanswould be
to use mice harboring both human immune cells and human hep-
atocytes (Figure 1). The study byWashburn et al. (2011) described
above paved the road to the development of such an animalmodel.
However, the selection of human immune cells on murine MHC
instead of HLA molecules may have precluded the development
of very efficient T and B cell responses. An alternative approach
would thus be to use hepatodeficient and immunodeficient HLA-
expressingmice in order to allow the engraftment of HLAmatched
human hematopoietic stem cells (hHSC) and human hepatocytes.
The selection of immune cells on HLA molecules and the recog-
nition of the hepatocytes as being from self might give a better
view of the immune response against HCV and allow the design
of efficient vaccines and new therapeutic products.
Unfortunately, the development of all hematopoietic com-
partments from hHSC in mice is not efficient because of the
inability of several mouse cytokines to stimulate human cells
(Manz, 2007; Legrand et al., 2009). In order to ameliorate the
immune reconstitution from hHSC, several approaches have been
attempted using injection of exogenous recombinant cytokines
or by creating transgenic or knock-in mice (reviewed in Will-
inger et al., 2011). However, to achieve a complete human immune
reconstitution, several different human cytokines and growth fac-
tors would be necessary. Moreover, several mouse strains with
different genetic backgrounds reject transplanted human cells
because of the inefficient interaction between human CD47 and
the mouse signal-regulatory protein alpha (SIRPα) expressed on
macrophages (Takenaka et al., 2007). This inability of human
CD47 to interact with mouse SIRPα leads to activation of the
phagocytic activity of macrophages (Takizawa and Manz, 2007).
In line with this observation, it has been shown that human pro-
genitor cells expressing mouse CD47 can efficiently be engrafted
in BRGmice leading to a better homeostasis of T- and NK-cells in
lymphoid organs (Legrand et al., 2011). Similarly, the same BRG
background, which is one of the most efficient to allow hHSC
transplantation, has been used to create human SIRPα transgenic
mice in order to improve engraftment of hHSC (Strowig et al.,
2011). In order to avoid genetic manipulations and selection pro-
cedures of the cells to be transplanted, which can be in limited
number at the time of the graft, other genetic backgrounds have
been investigated for their efficiency to accept xenogenic trans-
plantations. This lead to the selection of the non-obese diabetic
(NOD) background which appears to be the best recipient for
hHSC transplantation. Indeed, this strain exhibits a polymor-
phism of the gene encoding SIRPα, allowing a more efficient
binding to human CD47 (Takenaka et al., 2007; Takizawa and
Manz, 2007; Yamauchi et al., 2013). Therefore, the NOD back-
groundmay bemore suitable to introduce xenogenic cells without
the need of genetic modification in order to achieve high degree
of chimerism (reviewed in Ito et al., 2008). The recent advances in
the field of induced pluripotent stem cells (iPS) may allow in the
future to develop amousemodel engrafted with iPS-derived hepa-
tocytes and HSC from the same donor (Espejel et al., 2010; Huang
et al., 2011; Liu et al., 2011; Sekiya and Suzuki, 2011; Schwartz
et al., 2012; Wu et al., 2012). This might overcome the issues of
HLA-matching between the immune system and hepatocytes but
will not resolve HLA matching with the host. However, this strat-
egy using iPS cells, which could be available in large amount,
would be easier to implement than the use of hHSC and fetal
hepatocytes which are more complicated to access due to ethical
reasons.
The hu-IS/hu-Hep mouse model would certainly be the best
model to assess the immune responses against HCV, to decipher
more deeply the immunopathogenesis developed during chronic
infection, to exploreHCV-host interactions during acute infection
and to unravel themechanisms leading to virus eradication as well
as to develop vaccines and new therapeutic approaches.
GENETICALLY HUMANIZED MOUSE MODEL
Another explored approach in order to develop an immuno-
competent mouse model of HCV infection relies on genetic
modifications of mice by introducing essential human specific fac-
tors for the viral life cycle (Figure 1). It has previously been shown
that viral entry, the first step of HCV infection, requires the pres-
ence of at least two human cell surface factors, CD81 and OCLN
(Ploss et al., 2009). The study by Dorner et al. (2011) described
above has shown that adenoviral expression of human entry fac-
tors in mouse liver enables viral entry into murine hepatocytes
in vivo. HCV RNA replication thus appears to be the next and last
essential step to overcome in mouse cells in order to reconstitute
the entire viral life cycle since mouse cells are able to support viral
assembly and egress (Long et al., 2011). Indeed, it has been shown
that viral RNA is translated in mouse cells but is unable to repli-
cate efficiently (McCaffrey et al., 2002; Dorner et al., 2011). It is
worth noting that several studies have shown that HCV replicons
can replicate in murine cell lines (Zhu et al., 2003; Uprichard et al.,
2006; Frentzen et al., 2011), indicating that there are no dominant
murine inhibitory factors implied in the low replication of HCV
in mouse cells and that murine orthologs of host factor required
for viral replication are able to participate in the full life cycle
of HCV. The activation of mouse innate immune responses may
thus most likely be responsible for the limited HCV replication in
mouse cells (Schoggins and Rice, 2013). Indeed, it has been shown
that inactivation of several antiviral cellular molecules involved
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in innate immunity enhances HCV replication and allows HCV
production by mouse cells (Chang et al., 2006; Lin et al., 2010; Aly
et al., 2011; Vogt et al., 2013). It might thus be wise to ascertain in
vivo the relevance of these findings and to generate amousemodel
devoid of someof these innate immunepathways or knock-inmice
expressing human orthologs of these innate immune mediators.
CONCLUSIONS AND PERSPECTIVES
Since the development of the first small animal model of HCV
infection – the uPA-SCIDmousemodel (Mercer et al., 2001), other
increasingly sophisticated models emerged (Wu et al., 2005; Bissig
et al., 2010; Dorner et al., 2011; Washburn et al., 2011). Each of
these models allowed to significantly advance our understanding
of defined aspects of HCV infection and HCV-host interactions
and to pave the way for future animal models combining dif-
ferent characteristics and advantages of each model. Although
the uPA-SCID mouse model has been most intensively used as
a preclinical model in order to assess different classes of antivirals,
none of the current models prevails over the others with respect
to analysis of all aspects of viral infection (virus life cycle, immune
response, pathogenesis, vaccine development. . .). The combina-
tion of different technologies and efforts will ultimately lead to
the development of additional models better suited for the study
of HCV immunopathogenesis and vaccine development. Given
the natural history of HCV infection, requiring decades to evolve
toward an HCC, one may consider that obtaining HCV-induced
cirrhosis andHCCwill be highly challenging in rodents, whose life
expectancy is around 2 years. However, numerous models of HCC
based on the transgenic expression of HCV proteins have been
published (reviewed in Billerbeck et al., 2013), suggesting that
HCV infection-induced HCC may be achievable, provided that
sufficient host-responses are generated. As the chimpanzee model
has to be abandoned in favor of small rodent models, the well
known genetics of the mouse and the ease of modification of its
genome should put this animal first in line to become the next gold
standard for HCV research. Fully mouse or half human, the pos-
sibilities remain open. The complementarities of both approaches
will raise new perspectives in the field of animal research for HCV
and for the development of new therapeutic alternatives. The quest
for the“holyGrail”is on, but the road is still long and full of pitfalls.
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